Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma
Metabolites · 10.03.2026 · 16 (3) · 185
DOI: 10.3390/metabo16030185 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 10.03.2026. Verfasst von Matthew Abikenari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94304, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arbor Pharmaceuticals, Accuray, BMS, Novartis.
Abstract (Originalsprache)
Glioblastoma (GBM) is a universally fatal cancer for which the standard of care has remained largely unchanged for the last 20 years. Recent work has demonstrated that most therapeutic trials for GBM fail due to complex mechanisms of immunosuppression mediated by both the innate and adaptive immune systems. Various metabolic alterations in the tumor microenvironment help maintain this local and systemic immunosuppression, of which the axis of hypoxia-driven tryptophan degradation has garnered substantial attention over the last decade. This paper synthesizes a much-needed elucidation of the immunometabolic reshaping of glioma, myeloid, endothelial, and lymphoid cell lineages induced by hypoxia. The current paper critically evaluates the role of IDO1/TDO2-mediated breakdown of tryptophan and the consequent accumulation of kynurenine, a metabolite that triggers GCN2- and AHR-mediated CD8+ T-cell exhaustion and supports regulatory T-cell differentiation and expansion. Furthermore, we propose a synthesis of mechanistic evidence that establishes a role for the Trp-GCN2-ATF4-VEGFA axis in hypoxia-induced immunosuppression, supporting that pro-tumoral metabolic dysregulation is directly linked to angiogenesis. In GBM, hypoxia and tryptophan–kynurenine pathway dysregulation operate as an integrated metabolic circuit that drives widespread immunosuppression. These mechanisms can be captured by a metabolic signature shared across nearly every cell type in the GBM microenvironment. Drawing on recent spatial transcriptomic, metabolomic, and pharmacologic studies, we outline how this metabolic axis shapes disease biology and how it can be targeted to restore effective antitumor immunity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94304, USA.
ORCID-Profile: Matthew Abikenari, George Nageeb, Matthew Adam Sjoholm, Brandon Bergsneider, Jocelyn Valenzuela, James Poe
Förderung
- Arbor Pharmaceuticals, Accuray, BMS, Novartis
Zitieren
APA
Abikenari, M., Nageeb, G., Ha, J. H., Sjoholm, M. A., Liu, J., Bergsneider, B., Valenzuela, J., Poe, J., Bog Cho, K., Verma, R., Wu, C., Sanker, V., Medikonda, R., Kim, L. H., Choi, J., Banu, M. A., & Lim, M. (2026). Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma. Metabolites, 16(3), 185. https://doi.org/10.3390/metabo16030185
Vancouver
Abikenari M, Nageeb G, Ha JH, Sjoholm MA, Liu J, Bergsneider B, et al. Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma. Metabolites. 2026;16(3):185. doi:10.3390/metabo16030185
BibTeX
@article{Abikenari2026,
author = {Abikenari, Matthew and Nageeb, George and Ha, Joseph H and Sjoholm, Matthew Adam and Liu, Justin and Bergsneider, Brandon and Valenzuela, Jocelyn and Poe, James and Bog Cho, Kwang and Verma, Rohit and Wu, Caren and Sanker, Vivek and Medikonda, Ravi and Kim, Lily H and Choi, John and Banu, Matei A and Lim, Michael},
title = {Nexus of IDO1/Kynurenine Pathway to T-Cell Exhaustion: Hypoxia-Induced Tryptophan Metabolism in Glioblastoma},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {3},
pages = {185},
doi = {10.3390/metabo16030185}
}
EUVIMED